Clinical case reports
Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone.
Minami Une, Shinya Yamamoto, Honoka Fuse, Ryo Fujiwara, Junji Yonese, Kenjiro Noda
Published: 202510.1002/ccr3.71617
Abstract
Open AccessWe report two cases of metastatic castration-resistant prostate cancer (mCRPC) with long-term survival following treatment with abiraterone. Despite the generally temporary efficacy of abiraterone, both patients remained progression-free for over 5 years, suggesting that some mCRPC patients may achieve durable responses with abiraterone.